Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Quoin Pharmaceuticals, Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PIPE FINANCING INCLUDED PARTICIPATION FROM LEADING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS INCLUDING AIGH CAPITAL MANAGEMENT, SOLEUS CAPITAL, NANTAHALA CAPITAL, DIADEMA PARTNERS, STONEPINE CAPITAL MANAGEMENT, ADAR1 CAPITAL MANAGEMENT, AND VELAN CAPITAL, AMONG OTHERS PIPE FINANCING INCLUDED PARTICIPATION FROM LEADING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS INCLUDING AIGH CAPITAL MANAGEMENT, SOLEUS CAPITAL, NANTAHALA CAPITAL, DIADEMA PARTNERS, STONEPINE CAPITAL MANAGEMENT, ADAR1 CAPITAL MANAGEMENT, AND VELAN CAPITAL, AMONG OTHERS

QUOIN PHARMACEUTICALS ANNOUNCES PRIVATE PLACEMENT FINANCING OF UP TO $104.5 MILLION

NEW EPISODE HIGHLIGHTS THE SOCIAL AND EMOTIONAL IMPACT OF NETHERTON SYNDROME, THE IMPORTANCE OF SUPPORTIVE COMMUNITIES, AND THE URGENT NEED FOR AN APPROVED TREATMENT NEW EPISODE HIGHLIGHTS THE SOCIAL AND EMOTIONAL IMPACT OF NETHERTON SYNDROME, THE IMPORTANCE OF SUPPORTIVE COMMUNITIES, AND THE URGENT NEED FOR AN APPROVED TREATMENT

QUOIN PHARMACEUTICALS RELEASES FIFTH NETHERTON NOW VIDEO FEATURING WRITERS AND INFLUENCERS ALLIE AND KALEIGH FASANELLA, TWIN SISTERS LIVING WITH NETHERTON SYNDROME

ASHBURN, VA., AUG. 18, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (QUOIN OR THE COMPANY), A LATE CLINICAL STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND ORPHAN DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF ITS NEW CHIEF FINANCIAL OFFICER AS THE COMPANY ADVANCES ITS LEAD PRODUCT CANDIDATE, QRX003, THROUGH PIVOTAL CLINICAL STUDIES AND PREPARES FOR POTENTIAL COMMERCIALIZATION.

QUOIN PHARMACEUTICALS APPOINTS NEW CHIEF FINANCIAL OFFICER TO SUPPORT COMMERCIALIZATION STRATEGY

NEW EPISODE HIGHLIGHTS THE PAINFUL, OFTEN MISUNDERSTOOD REALITY OF LIVING WITH NETHERTON SYNDROME AND THE URGENT NEED FOR EFFECTIVE TREATMENTS NEW EPISODE HIGHLIGHTS THE PAINFUL, OFTEN MISUNDERSTOOD REALITY OF LIVING WITH NETHERTON SYNDROME AND THE URGENT NEED FOR EFFECTIVE TREATMENTS

QUOIN PHARMACEUTICALS RELEASES FOURTH EPISODE IN NETHERTON NOW VIDEO SERIES FEATURING INTERNATIONAL PATIENT ADVOCATE MANDY ALDWIN-EASTON

LEAD PRODUCT, QRX003, BEING TESTED IN TWO ACTIVE REGISTRATIONAL CLINICAL STUDIES FOR NETHERTON SYNDROME ACROSS THE U.S., EUROPE, AND THE MIDDLE EAST.

QUOIN PHARMACEUTICALS PROVIDES PRODUCT PORTFOLIO UPDATE

COMPANY CONTINUES TO ADVANCE QRX003 IN LATE-STAGE CLINICAL TRIALS IN NETHERTON SYNDROME PATIENTS REGULATORY MILESTONE PROVIDES 10 YEARS OF MARKET EXCLUSIVITY IN EUROPE UPON APPROVAL ASHBURN, VA., MAY 20, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS ANNOUNCES EUROPEAN MEDICINES AGENCY (EMA) GRANTS ORPHAN DRUG DESIGNATION FOR QRX003 FOR THE TREATMENT OF NETHERTON SYNDROME

ASHBURN, VA., MAY 14, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE COMPANY OR QUOIN), A LATE CLINICAL STAGE, SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON RARE AND ORPHAN DISEASES, TODAY ANNOUNCES POSITIVE INITIAL CLINICAL DATA FROM ITS ONGOING INVESTIGATOR PEDIATRIC PEELING SKIN SYNDROME CLINICAL STUDY.

QUOIN PHARMACEUTICALS ANNOUNCES INITIAL POSITIVE CLINICAL DATA FOR QRX003 FROM PEDIATRIC PEELING SKIN SYNDROME STUDY

ASHBURN, VA., APRIL 30, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE COMPANY OR QUOIN), A LATE CLINICAL STAGE, SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPEUTIC PRODUCTS THAT TREAT RARE AND ORPHAN DISEASES, TODAY ANNOUNCES THAT IT HAS RECEIVED WRITTEN NOTICE FROM THE LISTING QUALIFICATIONS DEPARTMENT OF THE NASDAQ STOCK MARKET LLC (NASDAQ) STATING THAT THE COMPANY HAS REGAINED COMPLIANCE WITH THE MINIMUM BID PRICE REQUIREMENT UNDER NASDAQ LISTING RULE 5550(A)(2).

QUOIN PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE RULE

EPISODE HIGHLIGHTS A TRULY REMARKABLE PATIENT STORY SPANNING 79 YEARS VIDEO FEATURES 79-YEAR-OLD NORMA COLES, BELIEVED TO BE AMONG THE EARLIEST INDIVIDUALS EVER EVALUATED FOR NETHERTON SYNDROME AND IS AVAILABLE ON THE COMPANY'S NETHERTON NOW WEBSITE ASHBURN, VA., APRIL 10, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD.

QUOIN PHARMACEUTICALS RELEASES SECOND EPISODE OF ITS LIVING WITH NETHERTON SERIES, AS PART OF ITS ONGOING NETHERTON NOW AWARENESS CAMPAIGN

ASHBURN, VA., APRIL 02, 2025 (GLOBE NEWSWIRE) -- QUOIN PHARMACEUTICALS LTD. (NASDAQ: QNRX) (THE COMPANY OR QUOIN), A LATE CLINICAL STAGE, SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPEUTIC PRODUCTS THAT TREAT RARE AND ORPHAN DISEASES, TODAY ANNOUNCES ADDITIONAL HIGHLY POSITIVE CLINICAL DATA FROM ITS ONGOING INVESTIGATOR PEDIATRIC NETHERTON SYNDROME (NS) STUDY. AFTER 6 WEEKS OF CONTINUED WHOLE BODY APPLICATION OF QRX003, THE SUBJECT'S SKIN REMAINS ALMOST COMPLETELY HEALED DEMONSTRATING THE DURABILITY OF ONGOING DAILY TREATMENT WITH THE PRODUCT. IN ADDITION, THE PATIENT HAS CONTINUED TO HAVE NO REQUIREMENT FOR PREVIOUSLY NECESSARY MEDICATIONS SUCH AS ANTIBIOTICS, ANTIVIRALS, ANTIHISTAMINES AND GLUCOCORTICOIDS. IMPORTANTLY, WITH THE PATIENT'S PRURITUS OR ITCH ALMOST COMPLETELY ELIMINATED, SHE CONTINUES TO EXPERIENCE ZERO NIGHTLY SLEEP DISTURBANCES WITHOUT THE NEED FOR ANY SEDATING MEDICATION, MARKING THE FIRST CONTINUOUS PERIOD OF UNINTERRUPTED SLEEP IN THE PATIENT'S LIFE. NO ADVERSE EVENTS HAVE BEEN REPORTED TO DATE AFTER 6 WEEKS OF WHOLE BODY TREATMENT WITH QRX003.

QUOIN PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE WHOLE BODY' CLINICAL DATA FROM ONGOING PEDIATRIC NETHERTON SYNDROME STUDY AND APPROVAL TO INITIATE TESTING OF A SECOND PEDIATRIC PATIENT

Quoin Pharmaceuticals, Ltd.

QNRX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Quoin Pharmaceuticals, Ltd.

QNRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

QNRX